Oxurion Receives Transparency Notifications Based on New Denominator
17 Noviembre 2022 - 1:00AM
Oxurion Receives Transparency Notifications Based on New
Denominator
Leuven, BELGIUM, Boston, MA, US
– November
17,
2022 – 8 AM
CET Oxurion NV (Euronext Brussels: OXUR) a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, with clinical stage assets in vascular
retinal disorders, today announced that, pursuant to Belgian
Transparency legislation1 it has received transparency
notifications as follows:
Following the issuance of new shares pursuant to
the Capital Commitment entered into with Negma Group Ltd., the
updated denominator for transparency notifications was 109,075,765
shares as of November 11, 2022: Information on the Total Number of
Voting Rights (Denominator) following Conversion Notice from NEGMA
| Oxurion NV)
Oxurion received transparency notification from
Negma Group indicating that as of November 16, it holds 0 common
shares. Oxurion also received transparency notification from
Fidelity Management & Research Company LLC that their 3,128,819
common shares have crossed below the lowest threshold (3%) by
virtue of a downward passive crossing.
In addition, by virtue of a downward passive
crossing, the following thresholds have been crossed:
- Novartis Pharma
AG’s 2,177,226 shares have crossed below the lowest threshold
(3%)
- Philippe
Vlerick/Balderma SA’s 3,580,787 shares have crossed below the
lowest threshold (3%)
- Thomas M. Clay’s
4,542,110 shares have crossed below the 5% threshold
Content of the
latest Negma Group Ltd.
Notification
Reason of the notification
Acquisition or disposal of voting securities or
voting rights
Notifications by
A person that notifies alone
Threshold that is crossed
Downward crossing of the lowest threshold
Denominator
109,075,765
Chain of controlled undertakings through which
the holding is effectively held
Not applicable
Notified details
See Annex 1 for this and prior transparency
notification of November
Content of the Fidelity Management &
Research Company LLC Notification
Reason of the notification
Passive crossing of a thresholdDownward crossing of the lowest
threshold
Notifications by
A parent undertaking or a controlling person
Threshold that is crossed
3%
Denominator
109,075,765
Notified details
See Annex 2
Chain of controlled undertakings through which
the holding is effectively held
Fidelity Management & Research Company LLC
is controlled by FMR LLC.
FMR LLC is not a controlled entity
About Oxurion
Oxurion (Euronext Brussels: OXUR) is a
biopharmaceutical company developing next generation standard of
care ophthalmic therapies, which are designed to improve and better
preserve vision in patients with retinal disorders including
diabetic macular edema (DME), the leading cause of vision loss in
working-age people, as well as other conditions. Oxurion intends to
play an important role in the treatment of retinal disorders,
including the successful development of THR-149, its novel
therapeutic for the treatment of DME. THR-149 is a potent plasma
kallikrein inhibitor being developed as a potential new standard of
care for the up to 50% of DME patients showing suboptimal response
to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium,
with corporate operations in Boston, MA. More information is
available at www.oxurion.com.
Important information about
forward-looking statements
Certain statements in this press release may be
considered “forward-looking”. Such forward-looking statements are
based on current expectations, and, accordingly, entail and are
influenced by various risks and uncertainties. The Company
therefore cannot provide any assurance that such forward-looking
statements will materialize and does not assume any obligation to
update or revise any forward-looking statement, whether as a result
of new information, future events, or any other reason. Additional
information concerning risks and uncertainties affecting the
business and other factors that could cause actual results to
differ materially from any forward-looking statement is contained
in the Company’s Annual Report. This press release does not
constitute an offer or invitation for the sale or purchase of
securities or assets of Oxurion in any jurisdiction. No securities
of Oxurion may be offered or sold within the United States without
registration under the U.S. Securities Act of 1933, as amended, or
in compliance with an exemption therefrom, and in accordance with
any applicable U.S. state securities laws.
For further information please
contact:
Oxurion NVTom GraneyChief Executive OfficerTel: +32 16 75 13
10tom.graney@oxurion.com Michael DillenChief Business
OfficerTel: +32 16 75 13 10michael.dillen@oxurion.com |
USConway CommunicationsBeth Kurthbkurth@conwaycommsir.com
ICR WestwickeChristopher BrinzeyTel: +1 617 835
9304Chris.Brinzey@westwicke.com |
ANNEX 1
Negma notification of November 16, 2022
A) Voting
rights |
Previous notification |
After the
transaction |
|
|
# of voting
rights |
# of voting
rights |
% of voting
rights |
Holders of voting rights |
|
Linked to securities |
Not linked to the securities |
Linked to securities |
Not linked to the securities |
Elaf Gassam |
0 |
0 |
|
|
|
|
- |
Negma Group Investment Ltd. |
0 |
0 |
|
|
|
- |
Negma Group Ltd. |
16,250,000 |
0 |
|
|
|
- |
Subtotal |
16,250,000 |
0 |
|
|
|
+ |
B) Equivalent
financial instruments |
After the
transaction |
|
Holders of
equivalent financial
instruments |
Type of
financial instrument |
Expiration
date |
Exercise period
or date |
# of
voting rights that may
be acquired if the
instrument is
exercised |
% of
voting rights |
Settlement |
|
|
|
|
|
|
|
+ |
TOTAL |
0 |
0.00% |
|
The totals
will be updated
once you have
clicked on
<CALCULATE>
TOTAL (A
& B) |
# of
voting rights |
% of
voting rights |
|
CALCULATE |
0 |
0.00% |
Negma notification of November 8, 2022
A) Voting
rights |
Previous notification |
After the
transaction |
|
|
# of voting
rights |
# of voting
rights |
% of voting
rights |
Holders of voting rights |
|
Linked to securities |
Not linked to the securities |
Linked to securities |
Not linked to the securities |
02/11/2022: Negma Group Ltd. Threshold: + 15 % |
0 |
15,000,000 |
|
16.16% |
|
|
- |
03/11/2022: Negma Group Ltd. Threshold: - 10 % |
|
8,828,255 |
|
|
|
- |
04/11/2022: Negma Group Ltd |
|
8,750,000 |
|
|
|
- |
7/11/2022: Negma Group Ltd. Threshold: - 3 % (see section 13) |
|
0 |
|
|
|
- |
Subtotal |
|
15,000,000 |
|
16.16% |
|
+ |
TOTAL |
15,000,000 |
0 |
16.16% |
0.00% |
|
B) Equivalent
financial instruments |
After the
transaction |
|
Holders of
equivalent financial
instruments |
Type of
financial instrument |
Expiration
date |
Exercise period
or date |
# of
voting rights that may
be acquired if the
instrument is
exercised |
% of
voting rights |
Settlement |
|
|
|
|
|
|
|
+ |
TOTAL |
0 |
0.00% |
|
TOTAL (A
& B) |
# of
voting rights |
% of
voting rights |
|
CALCULATE |
15,000,000 |
16.16% |
ANNEX 2
B) Equivalent
financial instruments |
After the
transaction |
|
Holders of
equivalent financial
instruments |
Type of
financial instrument |
Expiration
date |
Exercise period
or date |
# of
voting rights that may
be acquired if the
instrument is
exercised |
% of
voting rights |
Settlement |
Fidelity Management & Research Company LLC |
Stock Loan |
|
|
90,401 |
0.08% |
physical |
+ |
TOTAL |
90,401 |
0.08% |
|
TOTAL (A
& B) |
# of
voting rights |
% of
voting rights |
|
CALCULATE |
3,128,819 |
2.87% |
________
1. Article 14, first paragraph, of the Law of 2 May 2007 on
disclosure of major holdings.
- OXUR Transparency Notifications (EN) 2022.1117
Oxurion Nv (LSE:0G99)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Oxurion Nv (LSE:0G99)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024